October Pharma results, Q4 2022
Net profit, assets, equity and cash flow for Q4 2022, against the same period a year earlier, from the published financial statements.
Net profit21.88 millionEGP
Total assets950 millionEGP
Shareholders' equity426 millionEGP
Operating cash flow-15.18 millionEGP
In short
- October Pharma's net profit for Q4 2022 was about 21.88 million EGP.
- Total assets at the end of Q4 2022 were about 950 million EGP, and shareholders' equity about 426 million EGP.
- Operating cash flow for Q4 2022 was negative at 15.18 million EGP.
Key lines against the same period a year earlier
This periodYear earlierChange
Net profit21.88 million——
Gross profit95.99 million——
Total assets950 million——
Total liabilities524 million——
Shareholders' equity426 million——
Total liabilities and equity950 million——
Operating cash flow-15.18 million——
Investing cash flow-21.01 million——
Financing cash flow30.41 million——
Net change in cash-5.78 million——
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. Figures are as shown in the published statement summary; quarterly figures may be cumulative from the start of the fiscal year.
October Pharma's Q3 2026 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy